Trial Profile

Phase I Additional Study of Tolerance and Pharmacokinetics of Anlotinib in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary)
Indications Solid tumours
Focus Pharmacokinetics
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

15 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
15 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
24 Apr 2017 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com